BACKGROUND: Patients with primary brain tumors (PBTs) face uncertainty related to prognosis, symptoms, treatment response, and toxicity. The authors of this report examined the direct/indirect relations among patients' uncertainty, mood states, and symptoms. METHODS: In total, 186 patients with PBTs were accrued at various points in the illness trajectory. Data-collection tools included an investigator-completed clinician checklist, a patient-completed demographic data sheet, the Mishel Uncertainty in Illness Scale-Brain Tumor Form (MUIS-BT), the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT), and the Profile of Mood States-Short Form (POMS-SF). Structural equation modeling was used to explore correlations among variables. RESULTS: Participants were primarily white (80%) men (53%) with a variety of brain tumors. They ranged in age from 19 to 80 years (mean ± standard deviation, 44.2 ± 12.6 years). Lower functional status and earlier point in the illness trajectory were associated with greater uncertainty (P < .01 for both). Uncertainty (P < .05), except in the model of "confusion," and the 5 negative mood states measured by the POMS-SF were directly associated with symptom severity perceived by patients (P < .01 for all). The impact of uncertainty on perceived symptom severity also was mediated significantly by mood states. CONCLUSIONS: The results from the study clearly demonstrated distinct pathways for the relations between uncertainty-mood states-symptom severity for patients with PBTs. Uncertainty in patients with PBTs is higher for those who have a poor performance status and directly impacts negative mood states, which mediate patient-perceived symptom severity. This conceptual model suggests that interventions designed to reduce uncertainty or that target mood states may help lessen patients' perception of symptom severity, which, in turn, may result in better treatment outcomes and quality of life.
BACKGROUND:Patients with primary brain tumors (PBTs) face uncertainty related to prognosis, symptoms, treatment response, and toxicity. The authors of this report examined the direct/indirect relations among patients' uncertainty, mood states, and symptoms. METHODS: In total, 186 patients with PBTs were accrued at various points in the illness trajectory. Data-collection tools included an investigator-completed clinician checklist, a patient-completed demographic data sheet, the Mishel Uncertainty in Illness Scale-Brain Tumor Form (MUIS-BT), the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT), and the Profile of Mood States-Short Form (POMS-SF). Structural equation modeling was used to explore correlations among variables. RESULTS:Participants were primarily white (80%) men (53%) with a variety of brain tumors. They ranged in age from 19 to 80 years (mean ± standard deviation, 44.2 ± 12.6 years). Lower functional status and earlier point in the illness trajectory were associated with greater uncertainty (P < .01 for both). Uncertainty (P < .05), except in the model of "confusion," and the 5 negative mood states measured by the POMS-SF were directly associated with symptom severity perceived by patients (P < .01 for all). The impact of uncertainty on perceived symptom severity also was mediated significantly by mood states. CONCLUSIONS: The results from the study clearly demonstrated distinct pathways for the relations between uncertainty-mood states-symptom severity for patients with PBTs. Uncertainty in patients with PBTs is higher for those who have a poor performance status and directly impacts negative mood states, which mediate patient-perceived symptom severity. This conceptual model suggests that interventions designed to reduce uncertainty or that target mood states may help lessen patients' perception of symptom severity, which, in turn, may result in better treatment outcomes and quality of life.
Authors: Jennifer E Cahill; Lin Lin; Geri LoBiondo-Wood; Terri S Armstrong; Alvina A Acquaye; Elizabeth Vera-Bolanos; Mark R Gilbert; Nikhil S Padhye Journal: Neurooncol Pract Date: 2014-05-05
Authors: Galia Niv; Simona Bar Josef; Ofer Ben Bassat; Irit Avni; Lev Lictenstein; Yaron Niv; Sivia Barnoy Journal: Qual Life Res Date: 2017-02-08 Impact factor: 4.147
Authors: Alvina A Acquaye; Lin Lin; Elizabeth Vera-Bolanos; Mark R Gilbert; Terri S Armstrong Journal: Neuro Oncol Date: 2015-06-23 Impact factor: 12.300
Authors: Lin Lin; Lung-Chang Chien; Alvina A Acquaye; Elizabeth Vera-Bolanos; Mark R Gilbert; Terri S Armstrong Journal: J Neurooncol Date: 2015-03-25 Impact factor: 4.130
Authors: Mia Salans; Michelle D Tibbs; Minh-Phuong Huynh-Le; Anthony Yip; Kathryn Tringale; Roshan Karunamuni; Ronghui Xu; Anny Reyes; Anna Christina Macari; Tonya Pan-Weisz; Carrie R McDonald; Jona A Hattangadi-Gluth Journal: Int J Radiat Oncol Biol Phys Date: 2021-06-06 Impact factor: 7.038